Ribozyme as an approach for growth suppression of human pancreatic cancer

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology

Volumn 14, Issue 1, 2000, Pages 59-72

  Kijima, Hiroshi ^a   Scanlon, Kevin J ^b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b BAYER AG   (Germany)

Author keywords

Gene modulation; K ras oncogene; Pancreatic cancer; Ribozyme (catalytic RNA); Transfection; Vector

Indexed keywords

RIBOZYME;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; ONCOGENE K RAS; PANCREAS CANCER; POINT MUTATION;

EID: 0034022169     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:14:1:59     Document Type: Article

References (73)

1. 1. Scanlon, K. J., Ohta, Y., Ishida, H., Kijima, H., Ohkawa, T., Kaminski, A., Tsai, J., Horng, G., and Kushani-Sabet, M. (1995) Oligonucleitide-meiated modulation of mammalian gene expression. FASEB J. 6, 1288-1296.
2. 2. Kashani-Sabet, M. and Scanlon, K. J. (1995) Application of ribozymes to cancer gene therapy. Cancer Gene Ther. 2, 213-221.
3. 3. Christoffersen, R. E. and Mar, J. J. (1995) Ribozymes as human therapeutic agents. J. Med. Chem. 38, 2023-2037.
4. 4. Helene, C. (1994) Control of oncogene expression by antisense nucleic acids. Eur. J. Cancer, 30A, 1721-1726.
5. 5. Georges, R. N., Mukhopadhyay, T., Zhang, Y., Yen, N., and Roth, J.A. (1993) Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral ansisense K-ras construct. Cancer Res. 53, 1743-1746.
6. 6. Zhang, Y., Mukhopadhyay, T., Donehower, L. A., Georges, R. N., and Roth, J.A. (1993) Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer inhibits expression of the malignant phenotype. Hum. Gene Ther. 4, 451-460.
7. 7. Mercola, D. and Cohen, J. S. (1995) Ansisense approach to cancer gene therapy. Cancer Gene Ther. 2, 47-59.
8. 8. Castanotto, D., Rossi, J. J., and Sarver, N. (1994) Antisense catalytic RNAs as therapeutic agents. Adv. Pharmacol. 25, 289-317.
9. 9. Symons, R. H. (1994) Ribozymes. Curr. Opin. Structural Biol. 4, 322-330.
10. 10. Kijima, H., Ishida, H., Ohkawa, T., Kashani-Sabet, M., and Scanlon, K. J. (1995) Therapeutic applications of ribozymes. Pharmacol. Ther. 68, 247-267.
11. 11. Irie, A., Kijima, H., Ohkawa, T., Bouffard, D. Y., Suzuki, T., Curcio, L. D., Holm, P. S., Sassani, A., and Scanlon, K. J. (1997) Anti-oncogene ribozymes for cancer gene therapy. Adv. Pharmacol. 40, 207-257.
12. 12. Yamazaki, H., Kijima, H., Ohnishi, Y., Abe, Y., Oshika, Y., Tsuchida, T., Tokunaga, T., Tsugu, A., Ueyama, Y., Tamaoki, N., and Nakamura M. (1998) Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J. Natl. Cancer Inst. 90, 581-587.
13. 13. Scanlon, K. J. and Kashani-Sabet, M. (1998) Ribozymes as therapeutic agents: Are we getting closer? J. Natl. Cancer Inst. 90, 558-559.
14. 14. Juhl, H., Downing, S. G., Wellstein, A., and Czubayko, F. (1997) HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/ neu by ribozyme targeting. J. Biol. Chem. 272, 29482-29486.
15. 15. Jarvis, T. C., Wincott, F. E., Alby, L. J., McSwiggen, J. A., Beigelman, L., Gustofson, J., DiRenzo A., Levy, K., Arthur, M., Matulic-Adamic, J., Karpeisky, A., Gonzalez, C., Woolf, T. M., Usman, N., and Stinchcomb, D. T. (1996) Optimizing the cell efficacy of synthetic ribozymes. Site selection and chemical modifications of ribozymes targeting the protooncogene c-myb. J. Biol. Chem. 271, 29107-29112.
16. 16. Eastham, J. A. and Ahlering, T. E. ( 1996) Use of an anti-ras ribozyme to alter the malignant phenotype of a human bladder cancer cell line. J. Urol. 156, 1186-1188.
17. 17. James, H., Millis, K., and Gibson, I. (1996) Investigating and improving the specificity of ribozyme directed against the bcr-abl translocation. Leukemia 10, 1054-1064; Leukemia 10, 1676 (erratum).
18. 18. Bouffard, D. Y., Ohkawa, T., Kijima, H., Irie, A., Suzuki, T., Curcio, L. D., Holm, P. S., Sassani, A., and Scanlon, K. J. (1996) Oligonucleotide modulation of multidrug resistance. Eur. J. Cancer 32A, 1010-1018.
19. 19. Ohkawa, T., Kijima, H., Irie, A., Horng, G, Kaminski, A., Tsai, J., Kashfian, B. I., and Scanlon, K. J. (1996) Oligonucleitide modulation of multidrug resistance gene expression. in "Multidrug Resistance in Cancer Cells" (Eds. S. Gupta, and T. Tsuruo) pp. 413-433. Wiley & Sons, England.
20. 20. Matsushita, H, Kizaki, M., Kobayashi, H., Ueno, H., Muto, A., Takayama, N., Awaya, N., Kinjo, K., Hattori, Y., and Ikeda, Y. (1998) Restoration of retinoid sensitivity by MDR1 ribozymes in retinoic acid-resistant myeloid leukemic cells. Blood 91 2452-2458.
21. 21. Sarver, N., Cantin, E. M., Chang, P. S., Zaia, J. A., Ladne, P. A., Stephens, D. A., and Rossi, J. J. (1990) Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247, 1222-1225.
22. 22. Yu, M., Ojwang, J., Yamada, O., Hample, A., Rapapport, J., Looney, D., and Wong-Staal, F. (1993) A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type-1. Proc. Natl. Acad. Sci. USA 87, 6340-6344.
23. 23. Scanlon, K. J., Jiao, L., Funato, T., Wang, W., Tone, T., Rossi, J.J., and Kashani-Sabet, M. (1991) Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc. Natl. Acad Sci. USA 88, 10591-10595.
24. 24. Kashani-Sabet, M., Funato, T., Tone, T., Jiao, L., Wnag, W., Yoshida, E., Kashfian, B. I., Shitara, T., Wu, A. M., Moreno, J. G., Traweek, S. T., Ahlering, T. E., and Scanlon, K. J. (1992) Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res. Dev. 2, 3-15.
25. 25. Tone, T., Kashani-Sabet, M., Funato, T., Shitara, T., Yoshida, E., Kashfian, B. I., Horng, M., Fodstad, O., and Scanlon, K.J. (1993) Suppression of EJ cells tumorigenicity. In Vivo 7, 471-476.
26. 26. Funato, T., Shitara, T., Tone, T., Jiao, L., Kashani-Sabet, M., and Scanlon, K. J. (1994) Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme. Biochem. Pharmacol. 48, 1471-1475.
27. 27. Ohta, Y., Tone, T., Shitara, T., Funato, T., Jiao, L., Kashfian, B. I., Yoshida, E., Horng, M., Tsai, P., Lauterbach, K., Sashani-Sabet, M., Florenes, V. A., Fodstad, O., and Scanlon, K.J. (1994) H-ras ribozyme-mediated alteration of the human melanoma phenotype. Ann. N.Y. Acad. Sci. 716, 242-253.
28. 28. Kashani-Sabet, M., Funato, T., Florenes, V. A., Fodstad, O., and Scanlon, K. J. (1994) Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res. 54, 900-902.
29. 29. Scanlon, K. J., Ishida, H., and Kashani-Sabet, M. (1994) Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proc. Natl. Acad. Sci. USA 91, 11123-11127.
30. 30. Feng, M., Cabrera, G., Deshane, J., Scanlon, K. J., and Curiel, D. T. (1995) Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res. 55, 2024-2028.
31. 31. Ohta, Y., Kijima, H., Kashani-Sabet, M., and Scanlon, K. J. (1996) Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes. J. Invest. Dermatol. 106, 275-280.
32. 32. Maelandsmo, G. M., Hovig, E., Skrede, M., Engebraaten, O., Florenes, V. A., Myklebost, O., Grigorian, M., Lukanidin, E., Scanlon, K. J., and Fodstad, O. (1996) Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme. Cancer Res. 56, 5490-5498.
33. 33. Warshaw, A. L. and Fernandez-del Castillo, C. (1992) Pancreatic carcinoma. N. Engl. J. Med. 326, 455-456.
34. 34. Yamaguchi, K. and Enjoji, E. (1989) Carcinoma of the pancreas: a clinicopathologic study of 96 cases with immunohistochemical observations. Jap. J. Clin. Oncol. 19, 14-22.
35. 35. Ozaki, H. (1992) Improvement of pancreatic cancer treatment from the Japanese experience in the 1980's. Int. J. Pancreatol. 12, 5-9.
36. 36. Arbuck, S. G. (1990) Overview of chemotherapy for pancreatic cancer. Int. J. Pancreatol., 7, 209-222.
37. 37. Cohn, I. Jr. (1990) Overview of pancreatic cancer, 1989. Int. J. Pancreatol. 7, 1-11.
38. 38. Egan, S. E. and Weinberg, R. A. (1993) The pathway to signal achievement. Nature 365, 781-783.
39. 39. Slamon, D. J., deKernion, J. B., Verma, I. M., and Cline, M. J. (1984) Expression of cellular oncogenes in human malignancies. Science 224, 256-262.
40. 40. Barbacid, M. (1987) ras genes. Annu. Rev. Biochem. 56, 779-827.
41. 41. Bos, J. L. (1989) ras oncogenes in human cancer: A review. Cancer Res. 49, 4682-4689.
42. 42. Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., and Perucho, M. (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53, 549-554.
43. 43. Smit, V. T. H. B. M., Boot, A. J. M., Smit, A. M. M., Fleuren, G. J., Cornelisse, C. J., and Boss, J. L. (1988) Kras codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res. 16, 7773-7782.
44. 44. Grunewald, K., Lyons, J., Frohlich, A., Feichtinger, H., Weger, R. A., Schwab, G., Janssen, J. W. G., and Bartram, C. R. (1989) High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int. J. Cancer 43, 1037-1041.
45. 45. Mariyama, M., Kishi, K., Nakamura, K, Obata, H., and Nishimura, S. (1989) Frequency and types of point mutation at the 12th codon of the c-Ki-ras gene found in pancreatic cancers from Japanese patients. Jpn. J. Cancer Res. 80, 622-626.
46. 46. Tada, M., Yokosuka, O., Omata, M., Ohto, M., and Isono, K. (1990) Analysis of ras gene mutations in biliary and pancreatic tumors by polyperase chain reaction and direct sequencing. Cancer, 66, 930-935.
47. 47. Nagata, Y., Abe, M., Motoshima, K., Nakayama, E., and Shiku, H. (1990) Frequent glycine-to-aspartic acid mutations at codon 12 of c-Ki-ras gene in human pancreatic cancer in Japanese. Jpn. J. Cancer Res. 81, 135-140.
48. 48. Yanagisawa, A., Ohtake, K., Ohashi, K., Hori, M., Kitagawa, T., Sugano, H., and Kato, Y. (1993) Frequent c-K-ras oncogene activation in mucous cell hyperplasia of pancreas suffering from chronic inflammation. Cancer Res. 53, 953-956.
49. 49. DiGiuseppe, J. A., Hruban, R. H., Offerhaus, G. J. Clement, M.J., van den Berg, F. M., Cameron, J. L., and van Mansfeld, A. D. M. (1994) Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am. J. Pathol. 144, 889-895.
50. 50. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A laboratory manual. 2nd ed. Cold Spring Harbor Laboratory Press, New York.
51. 51. Ng, S-Y., Gunning, P., Eddy, R., Ponte, P., Leavitt, J., Show, T., and Kedes, L. (1985) Evolution of the functional human b-actin gene and its multi-pseudo gene family: Conservation of noncoding regions and chromosomal dispersion of psuedogenes. Mol. Cell. Biol. 5, 2720-2732.
52. 52. Gunning, P., Leavitt, J., Muscat, G., Ng, S-Y., and Kedes, L. (1987) A human β-actin expression vector system directs high-level accumulation of antisense transcripts. Proc. Natl. Acad. Sci. USA 84, 4831-4835.
53. 53. Lee, F-J. S., Moss, J., and Lin, L-W. (1992) A simplified procedure for hybridization of RNA blots. Biotechniques 13, 130-132.
54. 54. Kuroki, T. (1978) Agar plate culture and Lederberg-style replica plating of mammalian cells. Methods Cell Biol. 9, 157-178.
55. 55. Tsuchida, T., Kijima, H., Oshika, Y., Tokunaga, T., Yamazaki, H., Nakamura, M., Tamaoki, N., Scanlon, K. J., and Ueyama. Y. (1998) A hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer cells. Biochem. Biophys. Res. Commun. 253, 368-373.
56. 56. Kijima, H., Tsuchida, 8T., Kondo, H., Iida, T., Oshika, Y., Nakamura, M., Scanlon, K. J., Kondo, T., and Tamaoki, N. (1998) Hammerhead ribozymes against γ-glutamyleysteine synthetase mRNA down-regulate intracellular glutathione concentration of mouse islet cells. Biochem. Biophys. Res. Commun. 247, 697-703.
57. 57. Carter, G., Gilbert, C., and Lemoine, N. R. (1995) Effects of antisense oligonucleotides targeting K-ras expression in pancreatic cancer cell lines. Int. J. Oncol. 6, 1105-1112.
58. 58. Aoki, K., Yoshida, T., Sugimura, T., and Terada, M. (1995) Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res. 55, 3810-3816.
59. 59. Koizumi, M., Hayase, Y., Iwai, S., Kamiya, H., Inoue, H., and Ohtsuka, E. (1989) Design of RNA enzymes distinguishing a single base mutation in RNA. Nucleic Acids Res. 17, 7059-7071.
60. 60. Cech, T. R., and Uhlenbeck, O.C. (1994) Hammerhead nailed down. Nature 372, 39-40.
61. 61. Ohta, Y., Kijima, H., Kashani-Sabet, M., Scanlon, K. J. (1996) Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells. Nucleic Acids Res. 24, 938-942.
62. 62. Schrewe, H., Thompson, J., Bona, M., Hefta, L. A., Maruya, A., Hassauer, M, Shively, J. H., von Kleist, S., and Zimmermann, W. (1990) Cloning of the complete gene for carcinoembryonic antigen: Analysis of its promoter indicates a region conveying cell type-specific expression. Mol. Cell. Biol., 10, 2738-2748.
63. 63. Hauck, W. and Stanners, C. P. (1995) Transcriptional regulation of the carcinoembryonic antigen gene. J. Biol. Chem. 270, 3602-3610.
64. 64. Jolly, D. (1994) Viral vector systems for gene therapy. Cancer Gene Ther. 1, 51-64.
65. 65. Hodgson, C.P. (1995) The vector void in gene therapy. Biotechnology 13, 222-225.
66. 66. Hershlag, D. (1990) Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better. Proc. Natl. Acad. Sci. USA 88, 6921-6925,
67. 67. Anderson, W. F. (1992) Hum. gene therapy. Science 256, 808-813.
68. 68. Thompson, J. D., Macejak, D., Couture, L., and Stinchcomb, D. T. (1995) Ribozymes in gene therapy. Nature Med. 1, 277-278.
69. 69. Miller, A. D. and Rosman, G. J. (1989) Improved retroviral vectors for gene transfore and expression. Biotechniques 7, 980-990.
70. 70. Miller, D. G., Adam, M. A., and Miller, A. D. (1990) Gene transfer by retrovirus occures in cell that are actively replicating at the time of infection. Mol. Cell Biol. 10, 4239-1242.
71. 71. Becker, T. C., Noel, R.J., Coats, W. S., Gomez-Foix, A. M., Alam, T., Gerard, R. D., and Newgard, C. B. (1994) Use of recombinant adenovirus for metabolic engreering of mammalian cells. Methods Cell Biol. 43, 161-189.
72. 72. Graham, F. L. and Prevec, L. (1991) Manipulation of adenovirus vectors. Methods Mol. Biol. 7, 109-128.
73. 73. Kijima, H., Bouffard, D. Y., and Scanlon, K. J. (1996) Ribozyme-mediated reversal of human pancreatic carcinoma phenotype. in "Bone Marrow Transplantation - Basic and Clinical studies" (Eds. S. Ikehara, F. Takaku, and R. A. Good) pp. 153-163. Springer.